Fig. 2.
CT26 tumor rejection following DaRT combined with TLR9/TLR1,2 agonists. a Experimental scheme. CT26-bearing mice were treated with a 40–50 kBq DaRT seed in combination with CpG or XS15. For XS15 treatment, a 40 µg/50 µl peritumoral (p.t.) injection was given once a week for 3 weeks (three injections, first treatment on the day of DaRT insertion). For CpG treatment, a 100 µg/30 µl p.t. injection was given immediately prior to DaRT insertion and 20 µg/10 µl was administered intranasally (i.n.) three times thereafter, every 2 days. b Percent of tumor-bearing mice. pχ2 test < 0.05 for DaRT vs. DaRT + CpG. The presented results are based on cumulative data from two different experiments